ClinicalTrials.gg
RecruitingNCT07166263Updated Oct 1, 2026

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

An Early Phase 1 interventional study of NK510 and NK510 in Gastric Cancer (GC) and Colorectal Cancer, sponsored by Base Therapeutics (Shanghai) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Base Therapeutics (Shanghai) Co., Ltd. · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 1, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,184 studies in Stomach Neoplasms with a site in China — 481 open to participants now, 557 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
837th of 881
15 · median 87
Started
2025
with 116 others
Phase 1
93 of 1,184
48 open now
Primary completion
2027-06
later than 373 of 556 live
Registered
1,042nd of 1,184
by date

Among the 1,184 studies in Stomach Neoplasms with a site in China, this one is the 837th largest by planned enrollment of the 881 interventional ones that give a count, is one of 117 that started in 2025, is one of 93 in phase 1, reaches primary completion later than 373 of the 556 other live ones, and was the 1,042nd registered.

Stomach Neoplasms

3,404 studies on the registry are indexed under Stomach Neoplasms; 996 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

481 of the 1,184 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

476 more — sign in →

All 481 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 705 Stomach Neoplasms studies recruiting now, 377 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,184 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer and colorectal cancer.NK510 will be administered by intravenous infusion for systemic therapy and intraperitoneal perfusion therapy. The safety and efficacy of this treatment will be evaluated.

03

Conditions studied

  • Gastric Cancer (GC)
  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years, regardless of gender.
  2. Gastric cancer and colorectal cancer that are inoperable and unresectable with radiotherapy: For gastric cancer, molecular diagnosis confirms that it is not AFP-producing gastric cancer.
  3. Progressive disease or recurrence after receiving ≥ 2 .
  4. Patients are divided into two groups (Group A and Group B) based on the presence or absence of peritoneal . The criteria for determining peritoneal metastasis are as follows:

    1. Drained ascites ≥ 500ml, or B-ultrasound/CT in the supine position shows ascites depth ≥ 3cm.
    2. Peritoneal metastasis confirmed by any of the following criteria:

    i. Positive for exfoliated cancer cells in ascites. ii. Diagnosed as peritoneal metastatic carcinoma by imaging and symptoms. iii. Peritoneal metastasis confirmed by abdominal exploration. iv. Ascites confirmed as exudate by routine ascites examination and ascites biochemistry.

  5. At least one on CT or MRI according to v1.1 (Response Evaluation Criteria in Solid Tumors).
  6. performance status of 0-2.
  7. Expected survival period ≥ 3 months.
  8. Able to comply with the study protocol and follow-up procedures, and voluntarily sign the form for participation in this study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. Subjects with central nervous system (CNS) and/or carcinomatous meningitis with obvious symptoms.
  3. A history of other malignant tumors within the past 3 years.
  4. Subjects with active, known or suspected diseases [excluding type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, skin diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, or alopecia), or diseases that are not expected to relapse without external triggers].
  5. Subjects with a history of immunodeficiency, including positive test results, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
  6. A history of severe cardiovascular and cerebrovascular diseases, including but not limited to: severe cardiac rhythm or conduction abnormalities such as ventricular arrhythmias requiring clinical intervention, third-degree atrioventricular block, etc.; > 480 ms on 12-lead at rest; acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or higher cardiovascular and cerebrovascular events within 6 months before enrollment; (NYHA) cardiac function classification ≥ class II or (LVEF) \< 50%; clinically uncontrolled hypertension.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Systemic therapy with NK510 via intravenous infusion

    Systemic therapy with NK510 via intravenous infusion combined with PD-L1 or other regimens selected by the investigator

    Drug: NK510

  • Experimental
    Intraperitoneal perfusion therapy with NK510

    Intraperitoneal perfusion therapy with NK510 plus IL-2, PD-L1 or other regimens selected by the investigator for systemic therapy

    Drug: NK510

Interventions

  • DrugNK510

    NK510 will be administered through intravenous infusion, once a week for a total of six times.

  • DrugNK510

    NK510 will be administered through intraperitoneal perfusion on D1, D4, and D7 of the first week for a total of 3 times, with each 3-week cycle constituting a total of 2 cycles.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity

    To evaluate the DLT during N510 treatment

    Time frame: 6 weeks

  2. Overall response rate (ORR)

    Effectiveness Metrics

    Time frame: 6 weeks

  3. Puncture-free survival (PuFS)

    Effectiveness Metrics

    Time frame: 6 weeks

Secondary outcomes

  1. Progression-free survival (PFS)

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Nanjing Drum Tower Hospital, Affiliated to the Medical School of Nanjing University
    Nanjing, Jiangsu, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.

Of 167 industry-sponsored phase 1 interventional studies under Stomach Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 65. This study's planned 20 months is below that.

Counting every sponsor, half of 242 studies reached it within 51 months; a quarter within 33 and three quarters within 66.

Start moved once since we started tracking on Sep 25, 2026: Nov 2025 → Oct 2025, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 10, 2025
StartActual
Oct 16, 2025was Nov 2025
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
Nanjing Drum Tower Hospital, Affiliated to the Medical School of Nanjing University is now Recruiting
Oct 1, 2026
Start date
Nov 2025→Oct 16, 2025 (actual)
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Nanjing Drum Tower Hospital, Affiliated to the Medical School of Nanjing University · Nanjing, ChinaContact added g•••@163.com · •••2923
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    Nanjing Drum Tower Hospital, Affiliated to the Medical School of Nanjing University is now Recruiting
    Start date Nov 2025→Oct 16, 2025 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Nanjing Drum Tower Hospital, Affiliated to the Medical School of Nanjing University · Nanjing, ChinaContact added g•••@163.com · •••2923
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07166263
Lead sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Oct 16, 2025
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Base Edited Natural Killer Cells NK510

Start the discussion